Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

B-Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm
B-Cell Neoplasm

Hematologic Malignancy

B-Cell Neoplasm

CI-CAN-00000470Explore in graph →

HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items

NCIt: C27907

Overview
Statistics
Survival
Genomics29
Variants & evidence301
Drugs45
Trials7500
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (305)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 305 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
· Haematologica · 2012 · PMID 21993670 · validated civic_curation pubmed
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
· Nat Med · 2015 · PMID 26193344 · validated civic_curation pubmed
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.
· Blood · 2015 · PMID 25452615 · validated civic_curation pubmed
Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.
· Proc Natl Acad Sci U S A · 2018 · PMID 30487223 · validated civic_curation pubmed
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
· Blood Adv · 2018 · PMID 29507076 · validated civic_curation pubmed
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.
· Blood Adv · 2020 · PMID 32589730 · validated civic_curation pubmed
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
· Blood · 2019 · PMID 30602617 · validated civic_curation

Showing 201–225 of 305 publications

← Previous
1
…
8
9
10
…
13
Next →

Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia.

· Blood · 1986 · PMID 3455828 · validated civic_curation pubmed

TCF3 gene rearrangements in pediatric B-cell acute lymphoblastic leukemia-A single center experience.

· Int J Lab Hematol · 2023 · PMID 37058324 · validated civic_curation pubmed

B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.

· Front Oncol · 2019 · PMID 31921638 · validated civic_curation pubmed

Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.

· Br J Haematol · 2020 · PMID 32239695 · validated civic_curation pubmed

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

· Blood · 2004 · PMID 14726385 · validated civic_curation pubmed

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

· Blood · 2012 · PMID 22383795 · validated civic_curation pubmed

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

· N Engl J Med · 2015 · PMID 26352686 · validated civic_curation pubmed

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

· Leukemia · 2017 · PMID 27568520 · validated civic_curation pubmed

Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.

· J Exp Clin Cancer Res · 2009 · PMID 19284554 · validated civic_curation pubmed

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.

· Oncotarget · 2016 · PMID 27626698 · validated civic_curation pubmed

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

· Blood · 2017 · PMID 28408464 · validated civic_curation pubmed

Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.

· Blood Adv · 2019 · PMID 31725893 · validated civic_curation pubmed

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

· Nat Genet · 2015 · PMID 26214592 · validated civic_curation pubmed

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.

· Pathol Oncol Res · 2022 · PMID 36172171 · validated civic_curation pubmed

Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma.

· Ann Diagn Pathol · 2021 · PMID 33991782 · validated civic_curation pubmed

Concurrent EPOR::IGH fusion gene and numerous cytoplasmic granules in BCR::ABL1-like B-lymphoblastic leukemia.

· Pediatr Blood Cancer · 2024 · PMID 38302862 · validated civic_curation pubmed

From the archives of MD Anderson Cancer Center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH/EPOR fusion.

· Ann Diagn Pathol · 2020 · PMID 32330662 · validated civic_curation pubmed

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.

· Haematologica · 2021 · PMID 34196168 · validated civic_curation pubmed